NCT06616727View on ClinicalTrials.gov

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 26, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Recurrent Glioblastoma Multiforme (GBM)
Interventions
DRUG

SNC109

SNC-109 CAR-T Cells, first dose from 5×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC

Trial Locations (1)

Unknown

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Shanghai Simnova Biotechnology Co.,Ltd.

INDUSTRY